HK1086193A1 - Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- - Google Patents

Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Info

Publication number: HK1086193A1
Authority: HK; Hong Kong
Prior art keywords: prevention; treatment; breast cancer; hydroxy tamoxifen; tamoxifen
Prior art date: 2003-04-01

Application number

HK06107310.2A

Other languages

English (en)

Chinese (zh)

Inventor

Dominique Salin-Drouin

Jacques Wepierre

Philippe Rouanet

Original Assignee

Besins Healthcare Lu Sarl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-01

Filing date

2006-06-28

Publication date

2006-09-15

2006-06-28 Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl

2006-09-15 Publication of HK1086193A1 publication Critical patent/HK1086193A1/xx

Links

DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 title 1
206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

HK06107310.2A 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- HK1086193A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45896303P	2003-04-01	2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en)	2003-04-01	2003-12-15	Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number	Publication Date
HK1086193A1 true HK1086193A1 (en)	2006-09-15

Family

ID=33131847

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK08113909.5A HK1119950A1 (en)	2003-04-01	2006-06-28	Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
HK06107310.2A HK1086193A1 (en)	2003-04-01	2006-06-28	Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK08113909.5A HK1119950A1 (en)	2003-04-01	2006-06-28	Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Country Status (12)

Country	Link
US (2)	US7704516B2 (xx)
EP (3)	EP1952810B1 (xx)
JP (1)	JP5490346B2 (xx)
AU (1)	AU2003294973B2 (xx)
CA (1)	CA2519980C (xx)
ES (3)	ES2456958T3 (xx)
HK (2)	HK1119950A1 (xx)
IL (1)	IL170807A (xx)
MX (1)	MXPA05010597A (xx)
NO (1)	NO333805B1 (xx)
NZ (1)	NZ542499A (xx)
WO (1)	WO2004087123A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60327363D1 (de) *	2002-12-18	2009-06-04	Besins Int Lab	Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ATE324880T1 (de) *	2002-12-18	2006-06-15	Besins Int Lab	Behandlung von mastalgie mit4-hydroxy-tamoxifen
ES2456958T3 (es) *	2003-04-01	2014-04-24	Besins Healthcare Luxembourg Sarl	Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
DK1631275T3 (da) *	2003-06-09	2008-08-18	Ascend Therapeutics Inc	Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
US7968532B2 (en) *	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579857A1 (en) *	2004-03-22	2005-09-28	Laboratoires Besins International	Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) *	2004-03-22	2005-09-28	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
ES2306111T3 (es) *	2004-03-22	2008-11-01	Laboratoires Besins International	Tratamiento y prevencion de enfermedades benignas de mamas con 4-hidroxitamoxifeno.
US7507769B2 (en)	2004-03-22	2009-03-24	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) *	2004-10-14	2006-04-19	Laboratoires Besins International	4-Hydroxy tamoxifen gel formulations
WO2006040196A1 (en) *	2004-10-14	2006-04-20	Laboratoires Besins International	4-hydroxy tamoxifen gel formulations
EP2147674A1 (en) *	2008-07-24	2010-01-27	Besins Healthcare	Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en)	2009-10-27	2018-09-25	Besins Healthcare Luxembourg Sarl	Transdermal pharmaceutical compositions comprising active agents
CN106537139B (zh)	2014-05-12	2019-04-16	奎斯特诊断投资公司	通过质谱法定量他莫昔芬及其代谢物
KR101571098B1 (ko)	2014-07-16	2015-11-23	건국대학교 산학협력단	타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
JP6645431B2 (ja) *	2014-08-27	2020-02-14	東洋紡株式会社	低誘電接着剤組成物
US10278976B2 (en)	2014-12-12	2019-05-07	Mira Dx, Inc.	Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors
WO2017189976A1 (en)	2016-04-29	2017-11-02	Board Of Regents, The University Of Texas System	Targeted measure of transcriptional activity related to hormone receptors
CA3073836A1 (en)	2017-09-11	2019-03-14	Atossa Therapeutics, Inc.	Methods for making and using endoxifen
US20210009865A1 (en)	2018-03-07	2021-01-14	Toagosei Co., Ltd.	Adhesive composition, and adhesive layer-equipped layered product using same
WO2020023616A1 (en) *	2018-07-24	2020-01-30	Cornell University	Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2558373B1 (fr) *	1984-01-20	1987-07-03	Mauvais Jarvis Pierre	Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es)	1987-04-21	1994-01-16	Heumann Pharma Gmbh & Co	Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en)	1987-06-24	1991-09-03	Fujisawa Pharmaceutical Company, Ltd.	Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de)	1988-10-27	1990-05-03	Schering Ag	Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en)	1990-09-07	1993-02-23	University Of Georgia Research Foundation, Inc.	Triarylethylene carboxylic acids with estrogenic activity
TW218849B (xx) *	1991-05-17	1994-01-11	Bristol Myers Squibb Co
US5613958A (en)	1993-05-12	1997-03-25	Pp Holdings Inc.	Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de)	1994-03-08	1995-06-22	Hexal Pharma Gmbh	Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) *	1994-08-26	1998-02-24	Mary Kay Inc.	Barrier disruption treatments for structurally deteriorated skin
ATE200978T1 (de)	1996-03-29	2001-05-15	S W Patentverwertungs Ges M B	KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
EP1043986B1 (en)	1997-12-23	2003-04-16	Hexal Ag	Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) *	1998-04-20	2000-01-11	The Procter & Gamble Company	Skin care kit
NZ520015A (en)	1999-12-16	2003-03-28	Dermatrends Inc	Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de)	2000-07-12	2002-01-31	Hexal Ag	Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en)	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en)	2001-10-04	2003-04-14	Cellegy Pharmaceuticals, Inc.	Semisolid topical hormonal compositions and methods for treatment
EP1317921B1 (fr)	2001-12-07	2009-08-19	Besins International Belgique	Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations
ATE324880T1 (de)	2002-12-18	2006-06-15	Besins Int Lab	Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) *	2002-12-18	2009-06-04	Besins Int Lab	Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2456958T3 (es)	2003-04-01	2014-04-24	Besins Healthcare Luxembourg Sarl	Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
DK1631275T3 (da)	2003-06-09	2008-08-18	Ascend Therapeutics Inc	Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
US7968532B2 (en)	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en)	2004-03-22	2005-09-28	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en)	2004-03-22	2009-03-24	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en)	2004-03-22	2005-09-28	Laboratoires Besins International	Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en)	2004-10-14	2006-04-19	Laboratoires Besins International	4-Hydroxy tamoxifen gel formulations

2003
- 2003-12-15 ES ES08103014.0T patent/ES2456958T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP08103007.4A patent/EP1952810B1/en not_active Expired - Lifetime
- 2003-12-15 CA CA2519980A patent/CA2519980C/en not_active Expired - Lifetime
- 2003-12-15 ES ES03785958.4T patent/ES2483896T3/es not_active Expired - Lifetime
- 2003-12-15 WO PCT/EP2003/015029 patent/WO2004087123A1/en active Application Filing
- 2003-12-15 MX MXPA05010597A patent/MXPA05010597A/es active IP Right Grant
- 2003-12-15 ES ES08103007.4T patent/ES2456957T3/es not_active Expired - Lifetime
- 2003-12-15 JP JP2004570040A patent/JP5490346B2/ja not_active Expired - Lifetime
- 2003-12-15 NZ NZ542499A patent/NZ542499A/en not_active IP Right Cessation
- 2003-12-15 US US10/734,638 patent/US7704516B2/en not_active Expired - Lifetime
- 2003-12-15 AU AU2003294973A patent/AU2003294973B2/en not_active Expired
- 2003-12-15 EP EP08103014.0A patent/EP1941871B1/en not_active Expired - Lifetime
- 2003-12-15 EP EP03785958.4A patent/EP1608353B1/en not_active Expired - Lifetime
2005
- 2005-09-12 IL IL170807A patent/IL170807A/en active IP Right Grant
- 2005-09-30 NO NO20054526A patent/NO333805B1/no not_active IP Right Cessation
2006
- 2006-06-28 HK HK08113909.5A patent/HK1119950A1/xx not_active IP Right Cessation
- 2006-06-28 HK HK06107310.2A patent/HK1086193A1/xx not_active IP Right Cessation
2009
- 2009-01-14 US US12/353,890 patent/US8475814B2/en active Active

Also Published As

Publication number	Publication date
ES2456957T3 (es)	2014-04-24
MXPA05010597A (es)	2006-03-09
NO333805B1 (no)	2013-09-16
WO2004087123A1 (en)	2004-10-14
EP1952810B1 (en)	2014-01-08
CA2519980A1 (en)	2004-10-14
HK1119950A1 (en)	2009-03-20
ES2456958T3 (es)	2014-04-24
AU2003294973A1 (en)	2004-10-25
AU2003294973B2 (en)	2010-05-13
US7704516B2 (en)	2010-04-27
US20090186944A1 (en)	2009-07-23
EP1941871A1 (en)	2008-07-09
ES2483896T3 (es)	2014-08-08
EP1608353A1 (en)	2005-12-28
EP1952810A1 (en)	2008-08-06
EP1608353B1 (en)	2014-04-30
EP1941871B1 (en)	2014-01-08
NO20054526L (no)	2005-09-30
NZ542499A (en)	2008-10-31
JP2006514967A (ja)	2006-05-18
US8475814B2 (en)	2013-07-02
US20050031695A1 (en)	2005-02-10
IL170807A (en)	2014-08-31
JP5490346B2 (ja)	2014-05-14
CA2519980C (en)	2012-04-10

Legal Events

Date	Code	Title	Description
2023-12-29	PE	Patent expired	Effective date: 20231216

Publication	Publication Date	Title
HK1086193A1 (en)	2006-09-15	Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
EP1872124A4 (en)	2008-06-11	DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
EP1968607A4 (en)	2010-07-07	TREATMENT OF CANCER AND OTHER DISEASES
IL166475A0 (en)	2006-01-15	Improved treatment of cancer with glutamine
EP1667680A4 (en)	2008-10-08	COMBINED METHODS OF TREATING CANCER
IL178012A0 (en)	2006-12-31	Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP1663259A4 (en)	2009-07-29	COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1565187A4 (en)	2010-02-17	CANCER TREATMENT METHODS AND RELATED METHODS
EP1816996A4 (en)	2009-08-12	THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
EP1814909A4 (en)	2008-06-25	USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1812596A4 (en)	2010-07-14	TREATMENT OF CANCER AND COMPOSITIONS
EP1737472A4 (en)	2010-09-01	EFFECTIVE TREATMENT OF TUMORS AND CANCER USING TRICIRIBIN AND ASSOCIATED COMPOUNDS
EP1756166A4 (en)	2008-08-27	DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1587837A3 (en)	2005-12-07	Prostate cancer diagnosis and treatment
AU2003296757A8 (en)	2004-07-09	Reduction of breast density with 4-hydroxy tamoxifen
HK1125038A1 (en)	2009-07-31	Iontophoresis preparation for treatment of breast cancer and/or mastitis
IL158206A0 (en)	2004-05-12	Compositions and methods for the prevention and treatment of human prostate cancer
ZA200709542B (en)	2008-12-31	Combination therapy in the treatment of cancer
EP1635694A4 (en)	2008-05-21	PROCESS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
GB0326578D0 (en)	2003-12-17	Cancer diagnosis and therapy
AU2003293130A8 (en)	2004-06-18	Methods for identifying risk of breast cancer and treatments thereof
AU2003231803A8 (en)	2003-12-02	Treatment of cancer with mefloquire
GB0329416D0 (en)	2004-01-21	Treatment of cancer
EP1766051A4 (en)	2007-10-10	METHOD FOR IDENTIFYING BREAST CANCER RISK AND TREATMENTS THEREOF
EP1684795A4 (en)	2009-07-29	METHODS AND AGENTS FOR THE TREATMENT OF CANCER